Lon­za cites biotech fund­ing slow­down as it low­ers sales out­look for the year

Con­tract man­u­fac­tur­er Lon­za tem­pered its sales out­look for the rest of the year due in part to low­er-than-ex­pect­ed growth in the ser­vices it pro­vides to biotechs amid a slow­down in fund­ing.

Lon­za on Fri­day re­port­ed sales of CHF 3.1 bil­lion ($3.5 bil­lion) in the first half of the year, up 3.2% com­pared to CHF 2.98 bil­lion ($3.4 bil­lion) in the first half of last year. The com­pa­ny at­trib­uted the growth to its com­mer­cial CD­MO ser­vices, its bi­o­log­ics di­vi­sion and small mol­e­cule pro­duc­tion. But sales were al­so chal­lenged by a de­cline in de­mand for nu­traceu­ti­cal cap­sules and “biotech fund­ing con­straints” that neg­a­tive­ly af­fect­ed its ear­ly-stage busi­ness.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER